Radiopharm Theranostics Ltd (ASX:RAD) has appointed Dr Leila Alland to its board as a non-executive director.
The developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, has appointed Dr Alland, a paediatric haematologist-oncologist, for her strong track record in developing oncology drug products.
Dr Leila Alland.
Dr Alland has a wealth of experience including leadership roles at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, where she contributed to multiple successful drug approvals.
Currently chief medical officer of PMV Pharmaceuticals, a clinical-stage precision oncology company, Dr Alland also serves on the boards of several biopharmaceutical companies and is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research.
Previously, she served as chief medical officer of Affimed, a clinical-stage immuno-oncology company.
Dr Alland served as assistant professor of paediatrics at Albert Einstein College of Medicine and during her academic tenure, was awarded the James S McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer and blood disorders.
Radiopharm’s CEO & managing director Riccardo Canevari said of the appointment: “Dr Alland’s scientific and clinical expertise along with her impressive background in pharmaceutical drug development make her a valuable addition to our Board of Directors as we steer Radiopharm through a pivotal period of innovation and growth.”